Table 1 Patients’ characteristics (n = 79)
PD (n = 36) | TP (n = 7) | DP (n = 36) | p-value | |
|---|---|---|---|---|
Age, med (range), years | 75 (42–84) | 73 (68–79) | 75 (52–89) | 0.788 |
Sex, male, n (%) | 19 (52%) | 3 (43%) | 19 (53%) | 0.882 |
Neoadjuvant chemotherapy, n (%) | 15 (42%) | 4 (57%) | 17 (47%) | 0.727 |
Preoperative CA19–9 level, med (range), U/mL | 23 (0–9784) | 59 (3–727) | 18 (0–1638) | 0.454 |
Preoperative BW, med (range), kg | 54 (37–85) | 56 (47–73) | 58 (45–70) | 0.106 |
Preoperative BMI, med (range), kg/m2 | 21.2 (15.8–28.5) | 21.5 (19.9–29.9) | 23.1 (14.3–33.8) | 0.033 |
Preoperative SMI, med (range), kg/m2 | 6.4 (4.5–8.6) | 6.8 (5.6–7.1) | 6.4 (5.1–9.0) | 0.375 |
Preoperative serum albumin, med (range), g/ml | 3.6 (2.2–4.3) | 3.9 (2.5–4.3) | 3.8 (2.5–4.8) | 0.045 |
Preoperative PNI, med (range) | 42.3 (26.1–52.0) | 46.1 (29.2–54.6) | 43.9 (34.7–66.3) | 0.208 |
Preoperative GPS ≧1, n (%) | 17 (47%) | 2 (29%) | 9 (25%) | 0.131 |
Preoperative NRS2002 ≧3, n (%) | 18 (50%) | 1 (14%) | 6 (17%) | 0.005 |
Preoperative PERT, n (%) | 3 (8%) | 3 (43%) | 3 (8.3%) | 0.076 |
Resectability status, n (%) | ||||
 Resectable | 30 (83%) | 4 (57%) | 28 (78%) | 0.343 |
 Borderline resectable / Unresectable | 6 (17%) | 3 (43%) | 8 (22%) | |
Operating time, med (range), min | 499 (350–751) | 515 (345–699) | 373 (205–511) | < 0.001 |
Operative blood loss, med (range), ml | 460 (50–2000) | 640 (200–3570) | 200 (30–1200) | < 0.001 |
Pathological tumor size, med (range), mm | 27 (8–63) | 40 (18–80) | 26 (0–90) | 0.165 |
Lymph node metastasis, n (%) | 24 (67%) | 4 (57%) | 18 (50%) | 0.355 |
Adjuvant chemotherapy, n (%) | 34 (94%) | 6 (87%) | 29 (81%) | 0.187 |
Postoperative PERT, n (%) | 31 (86%) | 7 (100%) | 15 (42%) | < 0.001 |